Figure - PMC

Skip to main content

An official website of the United States government

Here's how you know

Here's how you know

Official websites use .gov
A .gov website belongs to an official government organization in the United States.

Secure .gov websites use HTTPS
A lock ( ) or https:// means you've safely connected to the .gov website. Share sensitive information only on official, secure websites.

View full-text article in PMC

. 2020 May 20;13:4397–4409. doi: 10.2147/OTT.S245554

Search in PMC
Search in PubMed
View in NLM Catalog
Add to search

© 2020 Chen et al.

This work is published and licensed by Dove Medical Press Limited. The full terms of this license are available at https://www.dovepress.com/terms.php and incorporate the Creative Commons Attribution – Non Commercial (unported, v3.0) License (http://creativecommons.org/licenses/by-nc/3.0/). By accessing the work you hereby accept the Terms. Non-commercial uses of the work are permitted without any further permission from Dove Medical Press Limited, provided the work is properly attributed. For permission for commercial use of this work, please see paragraphs 4.2 and 5 of our Terms (https://www.dovepress.com/terms.php).

PMC Copyright notice

ABLIM1 is a direct target of miR-1290. (A) The target genes of miR-1290 were predicted in RNA22, mirDIP (http://ophid.utoronto.ca/mirDIP/), miRDB (http://www.mirdb.org/), DIANA (http://diana.imis.athena-innovation.gr/DianaTools/index.php?r=microT_CDS/index), and TargetScan (http://www.targetscan.org/vert71/), and the predicted results of target genes were compared with genes with low expression of NPC in GSE12452 microarray dataset. There were three intersecting genes: OSBPL6, ABLIM1, CHL1. (B) The expression of ABLIM1 in the GSE12452 microarray dataset. (C) RNA22 predicts the binding site between miR-1290 and ABLIM1. (D) RT-qPCR for the detection of ABLIM1 mRNA expression in NPC and adjacent tissues (n = 36). (E) Western blot analysis for the detection of ABLIM1 protein expression in NPC and adjacent tissues (n = 36), * p < 0.05 vs adjacent tissues. (F) Dual-luciferase reporter gene assay to verify the binding relationship between miR-1290 and ABLIM1. (G) After overexpression or silencing of ZNF667-AS1 and miR-1290 in CNE-1 cells, RT-qPCR was used for the detection of ZNF667-AS1, miR-1290 and ABLIM1 expression. (H) After overexpression or silencing of ZNF667-AS1 and miR-1290 in CNE-1 cells, Western blot analysis was used for the detection of ABLIM1 expression. (I) Immunohistochemical staining for the detection of ABLIM1 protein expression in NPC and adjacent tissues (n = 36). (J) Pearson’s correlation test for the interactions between ABLIM1, ZNF667-AS1 and miR-1290. *p < 0.05 vs the oe-NC group. ^#p < 0.05 vs sh-NC group. ^&p < 0.05 vs the mimic NC group. ^@p < 0.05 vs the inhibitor NC group. Data are expressed as mean ± standard deviation. Paired t test is used for comparison of two groups. One-way analysis of variance is used for comparison among multiple groups. Each experiment was run in triplicate.

Abbreviations: ABLIM1, actin-binding LIM protein 1; miR-1290, microRNA-1290; RT-qPCR, reverse transcription quantitative polymerase chain reaction; NPC, nasopharyngeal carcinoma; ZNF667-AS1, zinc finger protein 667-antisense RNA 1; NC, negative control; oe, overexpression; shRNA, short hairpin RNA; WT, wild type; MUT, mutant; GAPDH, glyceraldehyde phosphate dehydrogenase.